{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1","upperLimit":"42","value":"21"},{"groupId":"OG001","lowerLimit":"13","upperLimit":"54","value":"33"},{"groupId":"OG002","lowerLimit":"0","upperLimit":"34","value":"13"},{"groupId":"OG003","lowerLimit":"16","upperLimit":"47","value":"31"}]}],"title":"grade II-IV acute graft versus-host-disease (GVHD)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"100","value":"0"},{"groupId":"OG001","lowerLimit":"3","upperLimit":"36","value":"19"},{"groupId":"OG002","lowerLimit":"0","upperLimit":"100","value":"0"},{"groupId":"OG003","lowerLimit":"1","upperLimit":"22","value":"11"}]}],"title":"grade III-IV acute graft versus-host-disease (GVHD)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"35"}],"units":"Participants"}],"description":"Percentage of participants with incidence of grade II-IV and grade III-IV acute graft versus-host-disease (GVHD).","dispersionType":"95% Confidence Interval","groups":[{"description":"Reduced-intensity conditioning and transplantation of human leukocyte antigen (HLA) -haploidentical related donor stem cells for patients \\<55 years old with hematopoietic cell transplantation Comorbidity Index (HCT-CI) ≤2\n\nHaplo HCT \\<55 years old: - Fludarabine (Flu)\n\n* Cyclophosphamide (Cy)\n* Melphalan (Mel)\n* Total body irradiation (TBI)\n* Non-T-cell depleted donor bone marrow stem cell infusion Day 0\n\nGVHD Prophylaxis: - Cyclophosphamide (Cy)\n\n* Tacrolimus (Tac)\n* Mycophenolate mofetil (MMF)","id":"OG000","title":"Arm A: Haplo-HCT <55 Years Old"},{"description":"Reduced-intensity conditioning and transplantation of human leukocyte antigen (HLA) -haploidentical related donor stem cells for patients ≥55 years old or younger with hematopoietic cell transplantation Comorbidity Index (HCT-CI) ≥3.\n\nHaplo HCT ≥55 years old: - Fludarabine (Flu)\n\n* Cyclophosphamide (Cy)\n* Melphalan (Mel): Dose reduction by 30%\n* Total body irradiation (TBI)\n* Non-T-cell depleted donor bone marrow stem cell infusion\n\nGVHD Prophylaxis: - Cyclophosphamide (Cy)\n\n* Tacrolimus (Tac)\n* Mycophenolate mofetil (MMF)","id":"OG001","title":"CLOSED Arm B: Haplo-HCT ≥55 Years Old"},{"description":"Reduced-intensity conditioning and transplantation of human leukocyte antigen (HLA) -haploidentical related donor stem cells for patients with hematopoietic cell transplantation Comorbidity Index (HCT-CI) ≤2 aged ≥55 and \\< 65 years old.\n\nGVHD Prophylaxis: - Cyclophosphamide (Cy)\n\n* Tacrolimus (Tac)\n* Mycophenolate mofetil (MMF)\n\nHaplo HCT ≥55 and \\< 65 years old: - Fludarabine (Flu)\n\n* Cyclophosphamide (Cy)\n* Melphalan (Mel)\n* Total body irradiation (TBI)\n* non-T-cell depleted donor bone marrow stem cells","id":"OG002","title":"Arm C: Haplo-HCT HCT-CI ≤2 Aged ≥55 and < 65yo"},{"description":"Reduced-intensity conditioning and transplantation of human leukocyte antigen (HLA) -haploidentical related donor stem cells for patients patients ≥65 and ≤75 years old OR any age group with hematopoietic cell transplantation Comorbidity Index (HCT-CI) ≥3.\n\nGVHD Prophylaxis: - Cyclophosphamide (Cy)\n\n* Tacrolimus (Tac)\n* Mycophenolate mofetil (MMF)\n\nHaplo HCT ≥65 and ≤75 years old: - Fludarabine (Flu)\n\n* Cyclophosphamide (Cy)\n* Total body irradiation (TBI)","id":"OG003","title":"Arm D: Haplo-HCT Aged ≥65 and ≤75yo OR Any Age HCT-CI ≥3"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"day 100","title":"Incidence of Grade II-IV and Grade III-IV Acute Graft Versus-host-disease (GVHD)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}